MMP2, MMP9, VEGF on placenta previa expression and its clinical significance

Status

Recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16008413

Enrollment

Unknown

Registered

2016-05-04

Start date

2016-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pernicious placenta previa

Interventions

observation group :not intervention

Eligibility

Sex/Gender

Female

Age

18 Years to 48 Years

Inclusion criteria

Inclusion criteria: 1. aged 18-48 years old; 2. Diagnosis of placenta previa; or history of cesarean section, abortion, medical abortion, ectopic pregnancy, uterine cavity operation; 3. pregnancy weeks 28-42 weeks.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of gestational diabetes mellitus or preeclampsia; 2. can not expressed or understood informed consent; 3. unable or unwilling to complete communication research; 4. Participating in clinical trials.

Design outcomes

Primary

Measure	Time frame
the differenct expression of MMP2, MMP9, VEGF in plasma and placental tissue;	—

Countries

China

Contacts

Public ContactChen Zhengqiong

Department of gynecology and obstetrics of Xinqiao Hospital, Third Military Medical University

13883322771@139.com+86 13883322771

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026